Cargando…
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma
Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because of lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as a novel therapeutic target for GBM in chimeric antigen receptor (CAR) T cell therapy...
Autores principales: | Tang, Xin, Zhao, Shasha, Zhang, Yang, Wang, Yuelong, Zhang, Zongliang, Yang, Meijia, Zhu, Yanyu, Zhang, Guanjie, Guo, Gang, Tong, Aiping, Zhou, Liangxue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713854/ https://www.ncbi.nlm.nih.gov/pubmed/31485480 http://dx.doi.org/10.1016/j.omto.2019.07.002 |
Ejemplares similares
-
B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors
por: Zhang, Zongliang, et al.
Publicado: (2020) -
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
por: Yang, Meijia, et al.
Publicado: (2020) -
Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
por: Tang, Xin, et al.
Publicado: (2021) -
Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021) -
Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities
por: Wang, Guoqing, et al.
Publicado: (2022)